Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.07.2019 | Case report

Cyclophosphamide/dexamethasone/thalidomide

Fatigue: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A retrospective study involving 68 patients with amyloid light-chain amyloidosis with kidney involvement treated between June 2012 and January 2018, a patient [age and sex not stated] was described, who developed fatigue following treatment with cyclophosphamide, thalidomide and dexamethasone. …
Literatur
Zurück zum Zitat Liu B, et al. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. Clinical Therapeutics 41: 1186-1198, No. 6, Jun 2019. Available from: URL: https://doi.org/10.1016/j.clinthera.2018.12.003 - China Liu B, et al. Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. Clinical Therapeutics 41: 1186-1198, No. 6, Jun 2019. Available from: URL: https://​doi.​org/​10.​1016/​j.​clinthera.​2018.​12.​003 - China
Metadaten
Titel
Cyclophosphamide/dexamethasone/thalidomide
Fatigue: case report
Publikationsdatum
01.07.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-64491-0

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Daclizumab

Case report

Bleomycin

Case report

Piroxicam